ZURICH (Reuters) – Drugmaker Roche’s novel cancer immunotherapy tiragolumab has been granted breakthrough therapy designation by the U.S. Food and Drug Administration in combination with Roche’s Tecentriq in the treatment of non-small cell lung cancer, the Swiss company said on Tuesday.
The designation had been granted based on results of a phase II CITYSCAPE trial, Roche said.
(Reporting by Brenna Hughes Neghaiwi, editing by Silke Koltrowitz)
Nembhard’s late 3 gives Pacers 111-106 victory over Knicks, cut NY’s lead to 2-1
Panthers take a 2-1 series lead over the Bruins, scoring 4 power-play goals in a 6-2 victory
Andrew Nembhard’s late 3 gives Pacers 111-106 victory over Knicks. Indiana moves within 2-1
Man pleads guilty in theft of bronze Jackie Robinson statue from Kansas park
Sean Burroughs, former MLB player, Little League World Series and Olympic champion, dies at 43
WABC Radio suspends Rudy Giuliani for flouting ban on discussing discredited 2020 election claims
US plans to impose major new tariffs on EVs, other Chinese green energy imports, AP sources sayHere’s what to know about conservatorships and how Brian Wilson’s case evolved
It’s not a matter of if a hurricane will hit Florida, but when, forecasters say
Specialty lab exec gets 10-year prison term for 11 deaths from tainted steroids in Michigan
Here’s what to know about conservatorships and how Brian Wilson’s case evolved
Specialty lab exec gets 10-year prison term for 11 deaths from tainted steroids in Michigan
US pledges money and other aid to help track and contain bird flu on dairy farms
A cyberattack forces a big US health system to divert ambulances and take records offline
